Versartis, Inc.

Versartis presents positive preclinical data on 2 product candidates at ENDO 09

Versartis has presented positive preclinical data on its two product candidates, VRS-317 and VRS-826, which have the potential to extend half-life of drugs. The company's compounds have shown in vivo potency equal to daily hGH and sustained plasma levels without toxicity.

SourceVersartis, Inc.·DateJun 10, 2009

Versartis publishes 2 preclinical abstracts at American Diabetes Association meeting

Versartis announces preclinical abstracts on its two product candidates VRS-859 and VRS-808, which utilize Amunix's rPEG technology to extend biologics' half-life. The compounds aim to reduce dosing frequency and side effects in type 2 diabetes and prevent nocturnal hypoglycemia in type 1 diabetes.

SourceVersartis, Inc.·DateJun 5, 2009